Catalog No.
Product Name
Application
Product Information
Citations
-
FEN1 Inhibitor
FEN1-IN-5 is a potent inhibitor of Flap endonuclease-1 (FEN1) with an IC50 of 12 nM. FEN1 plays a crucial role in DNA repair processes, particularly in the maturation of Okazaki fragments during DNA replication. This compound serves as a valuable tool in research applications aimed at dissecting the mechanisms of DNA repair and exploring potential therapeutic targets for conditions associated with FEN1 dysfunction. -
FEN1 Inhibitor
FEN1-IN-6 is a potent inhibitor of Flap endonuclease-1 (FEN1), with an IC50 of 10 nM. This compound plays a significant role in cellular mechanisms for DNA damage repair, enhancing research into DNA repair processes. Additionally, FEN1-IN-6 exhibits activity against the related endonuclease xeroderma pigmentosum G (XPG) with an IC50 of 23 nM, making it a valuable tool for studying nucleic acid metabolism and repair pathways. -
FEN1 Inhibitor
FEN1-IN-3 is a selective inhibitor of human flap endonuclease-1 (hFEN1), a crucial enzyme involved in DNA replication and repair. With an EC50 value of 6.8 µM, FEN1-IN-3 effectively stabilizes hFEN1, making it a valuable tool for studying DNA metabolic processes. This compound is suitable for research applications focused on cancer biology, gene expression regulation, and the exploration of therapeutic strategies targeting DNA repair mechanisms. -
FLAP Inhibitor
(S)-BI 665915 is a potent FLAP (5-lipoxygenase-activating protein) inhibitor with an IC50 of 1.7 nM, effectively targeting FLAP binding. This compound demonstrates functional inhibition of FLAP in human whole blood with an IC50 of 45 nM and exhibits favorable drug metabolism and pharmacokinetics (DMPK) across species. (S)-BI 665915 provides dose-dependent inhibition of leukotriene B4 (LTB4) production, making it a valuable tool for research into inflammatory responses and related biological pathways. -
FLAP Inhibitor
BI 665915 is a potent oral inhibitor of the 5-lipoxygenase-activating protein (FLAP). By inhibiting FLAP, this compound effectively blocks the biosynthesis of leukotriene B4 (LTB4), making it a valuable tool for exploring inflammatory pathways. BI 665915 has potential applications in research related to various inflammatory diseases, including those affecting the respiratory and cardiovascular systems. -
FLAP Inhibitor
L-669083 is a potent FLAP (5-lipoxygenase-activating protein) inhibitor that specifically targets leukotriene biosynthesis. It is structurally derived from a combination of indole and quinoline, showcasing significant activity in disrupting leukotriene production. Research applications include studying inflammatory responses and evaluating the role of leukotrienes in various disease models, making L-669083 a valuable tool in pharmacological investigations related to inflammation and related pathologies. -
Leukotriene Biosynthesis Inhibitor
L 689037 is a potent leukotriene biosynthesis inhibitor that targets the 5-lipoxygenase-activating protein (FLAP). This compound effectively disrupts the synthesis of leukotrienes, which are mediators of inflammation. L 689037 is valuable for research applications related to asthma and inflammatory bowel disease, aiding in the investigation of therapeutic strategies to mitigate these inflammatory conditions. -
FLAP Inhibitor
AM103 (free acid) is a selective inhibitor of 5-lipoxygenase activating protein (FLAP), effectively blocking the initial step of the leukotriene biosynthetic pathway. This compound demonstrates significant inhibition of leukotriene B4 and cysteinyl leukotriene production, exhibiting notable anti-inflammatory properties in murine models of chronic lung inflammation. Additionally, AM103 (free acid) has been shown to enhance survival in mice challenged with platelet-activating factor, making it a valuable tool for research into respiratory disorders, including asthma. -
FLAP Antagonist
ALR-6 is a selective antagonist of the 5-lipoxygenase-activating protein (FLAP), known for its anti-inflammatory properties. This compound effectively inhibits the formation of 5-LOX products by more than 80% in pro-inflammatory M1 monocyte-derived macrophages (MDM), while demonstrating minimal direct inhibition of 5-LOX activity. ALR-6 is valuable for research applications aimed at exploring inflammatory pathways and potential therapeutic interventions in inflammatory diseases. -
FLAP Inhibitor
FLAP-IN-1 is a potent 5-lipoxygenase-activating protein (FLAP) inhibitor, exhibiting an IC50 value of 654 nM. This compound is useful for investigating the role of FLAP in inflammatory pathways and its potential implications in cardiovascular disease research. Researchers can leverage FLAP-IN-1 to explore therapeutic strategies targeting leukotriene biosynthesis and related conditions. -
FEN1 Inhibitor
FEN1-IN-8 is a selective inhibitor of flap endonuclease 1 (FEN1), exhibiting an IC50 of less than 100 nM for FEN1 and a range of 100 nM to 1 μM for exonuclease 1 (EXO1). This compound serves as a valuable tool for studying the role of FEN1 in colorectal and gastric cancers, providing insights into tumor biology and potential therapeutic pathways. FEN1-IN-8 is suitable for research applications focused on understanding DNA repair mechanisms and their implications in cancer progression. -
FLAP Antagonist
ALR-27 is a selective antagonist of the 5-lipoxygenase activating protein (FLAP), exhibiting significant anti-inflammatory properties. This compound effectively inhibits the formation of 5-LOX products by more than 80% in pro-inflammatory M1 macrophage-derived macrophages (M1-MDM), without directly inhibiting 5-LOX activity. Additionally, ALR-27 reduces the production of prostaglandins and leukotrienes in neutrophils while promoting the synthesis of specialized pro-resolving mediators in distinct human macrophage phenotypes. These characteristics make ALR-27 valuable for research in inflammation and immune response modulation. -
Galectin-3 Inhibitor
Olitigaltin is a synthetic inhibitor of galectin-3, demonstrating a high binding affinity with a Kd value of 68 nM. This compound exhibits significantly lower affinity for galectin-1 and galectin-7, with Kd values of 0.22 μM and 38 μM, respectively. Olitigaltin is valuable for research applications investigating the role of galectin-3 in various biological processes, including inflammation, fibrosis, and cancer progression. -
Galectin Inhibitor
Thiodigalactoside is a potent inhibitor of galectins, specifically targeting GAL1 and GAL3 with Kd values of 24 μM and 49 μM, respectively. As a non-metabolizable disaccharide, it demonstrates significant anti-inflammatory and anti-cancer properties. Additionally, Thiodigalactoside has been shown to effectively reduce body weight gain in diet-induced obese rat models, making it a valuable tool for studying metabolic disorders and galectin-related diseases. -
Gal-3 Inhibitor
Selvigaltin (GB1211) is an orally active inhibitor of galectin-3, exhibiting a potent IC50 of 12 nM in rabbit models. This compound demonstrates significant anti-tumor activity by effectively reducing galectin-3 levels in the liver, which leads to decreased biomarkers associated with liver function, inflammation, and fibrosis. Additionally, Selvigaltin downregulates the expression of key inflammatory and fibrotic markers, such as IL6, TGFβ3, SNAI2, and collagen, while also restoring T-cell activity, thereby impeding tumor growth and metastasis. It serves as a valuable tool for research into therapeutic strategies targeting galectin-3 related disorders. -
Galectin-3 Inhibitor
β-Lactose is a disaccharide that serves as an inhibitor of galectin-3, a protein involved in various biological processes, including cell adhesion and immune response. Its ability to modulate galectin-3 activity makes it a valuable tool in research pertaining to cancer, inflammation, and fibrosis. Additionally, β-lactose can be utilized as a substrate in studies of lactose metabolism and as a model compound for investigating carbohydrate-protein interactions. -
Galectin-3 Antagonist
Galectin-3 antagonist 1 is a specific inhibitor of Galectin-3, exhibiting a Kd value of 5.3 μM. This compound also demonstrates binding affinities to other galectins, with Kd values of 250 μM for Gal-4N, 18 μM for Gal-4C, and 450 μM for Gal-8C. It serves as a valuable tool for investigating the role of Galectin-3 in various biological processes and its implications in disease states, making it suitable for research in cancer, inflammation, and fibrosis. -
immunosuppressive
4,5-Dibromo-2-pyrrolic acid is an immunosuppressive compound that acts by inhibiting the proliferative response of splenocytes. This compound has been shown to significantly reduce the activation of immune cells in response to suboptimal concentrations of the mitogen concanavalin A (Con A). Its primary applications include research in immune regulation and the study of immunosuppressive mechanisms. -
galectin-8N Inhibitor
Galectin-8N-IN-1 is a selective inhibitor targeting galectin-8N, exhibiting a Kd value of 1.8 μM. This compound serves as a valuable ligand for galectin-8N studies and plays a critical role in researching immune system mechanisms. Its potent inhibition of galectin-8N makes it an essential tool for exploring immune modulation and related biochemical pathways. -
Galectin-1 Inhibitor
GB1908 is a selective oral inhibitor of galectin-1, demonstrating Ki values of 57 nM and 72 nM for human and mouse galectin-1, respectively. This compound exhibits over 50-fold selectivity for galectin-1 compared to galectin-3. GB1908 serves as a valuable tool in the investigation of lung cancer and related therapeutic strategies, facilitating research into the role of galectin-1 in tumor progression and immune modulation. -
Click Chemistry
Thiobis-β-Galactose-propyne serves as a versatile click chemistry reagent with an alkyne functional group, enabling copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions. Primarily, it acts as a multivalent inhibitor of galectin-3 (Gal-3), a protein implicated in various metabolic processes associated with cancer progression. This compound is suitable for applications in biochemical research focused on galectin-3-related pathways and provides a valuable tool for the development of targeted therapeutic strategies. -
Galectin-1 Inhibitor
DB21 is a Galectin-1 antagonist that functions as an allosteric inhibitor of galectin-1 binding to cell surface glycans. This dibenzofuran-conjugated peptidomimetic demonstrates significant inhibition of angiogenesis and tumor growth in models of melanoma, lung adenocarcinoma, and ovarian cancer. Its ability to disrupt galectin-1 interactions positions DB21 as a valuable tool for cancer research and therapeutic development. -
Galectin-3/Galectin-8C Inhibitor
Galectin-3/Galectin-8-IN-1 is a dual inhibitor targeting the C-terminal domains of Galectin-3 and Galectin-8, exhibiting Kd values of 4.12 μM and 6.04 μM, respectively. This compound effectively hinders migration in MRC-5 lung fibroblast cells, highlighting its potential role in modulating cellular processes. Galectin-3/Galectin-8-IN-1 is applicable in cancer research and studies focusing on tissue fibrosis, offering insights into therapeutic strategies for these conditions. -
Galectin-3 Inhibitor
GB2095 is a selective inhibitor of galectin-3, demonstrating strong binding affinity with human (KD = 0.036 μM) and mouse (KD = 0.35 μM) variants. This compound exhibits significant anti-tumor activity in syngeneic mouse models, specifically for breast and melanoma cancers. GB2095 is valuable for research applications aimed at understanding the role of galectin-3 in cancer progression and therapeutic interventions. -
Galectin 4C Inhibitor
Galectin-4-IN-3 is a selective inhibitor of Galectin 4C, exhibiting a Kd of 160 μM. This compound is valuable for studies investigating the role of Galectins in cell-cell adhesion, immune response regulation, and cancer progression. Researchers can utilize Galectin-4-IN-3 to explore potential therapeutic strategies targeting Galectin-mediated pathways in various disease contexts. -
Galectin-8N Inhibitor
Galectin-8-IN-2 is a selective inhibitor of galectin-8N, a member of the galectin family implicated in various biological processes. This compound exhibits significant inhibitory activity, making it a valuable tool for investigating galectin-mediated pathways and their roles in disease mechanisms. It is particularly useful for research focused on cancer, inflammation, and immune response modulation. -
Galectin-8N Activator
Galectin-8-IN-1 is a selective ligand targeting the N-terminal domain of galectin-8 (galectin-8N), exhibiting a dissociation constant (Kd) of 48 μM. This compound demonstrates a 15-fold selectivity over galectin-3, as well as significantly enhanced selectivity against other mammalian galectins. Galectin-8-IN-1 is valuable for research applications focused on galectin biology, immune responses, and cell signaling pathways. -
Galectin 4 Inhibitor
Galectin-4-IN-2 is a potent inhibitor of galectin-4C, exhibiting a dissociation constant of 1.6 mM. This compound is valuable for studies investigating the role of galectin-4 in various biological processes, including cell adhesion, immune response, and cancer biology. Research applications include elucidating the mechanisms of galectin-mediated pathways and exploring therapeutic strategies targeting galectin proteins in disease models. -
Galectin-3 Inhibitor
Galectin-3-IN-4 is a selective carboxamide inhibitor targeting galectin-3, with an IC50 of 21 nM for human galectin-3 and 167 nM for mouse galectin-3. This compound demonstrates significant selectivity, showing much higher IC50 values of 1580 nM and 2750 nM for human galectin-1 and galectin-9, respectively. Galectin-3-IN-4 is orally bioavailable, making it a valuable tool for research into the role of galectin-3 in various biological processes, including cancer, inflammation, and fibrosis. -
Gal-3 Inhibitor
Galectin-3-IN-2 is a potent multivalent inhibitor of galectin-3 (Gal-3), exhibiting an IC50 value of 8.3 μM. Galectin-3 is involved in various cancer-related metabolic processes, making this compound valuable for research into cancer biology and therapeutic development. Its application as a Gal-3 inhibitor allows for the exploration of its role in tumor progression, metastasis, and immune response modulation. -
Galectin-3 Inhibitor
Galectin-3-IN-6 is a potent inhibitor of galectin-3, displaying an IC50 of 12 nM against human galectin-3 and 12.6 nM against the mutant murine galectin-3 (V160A), along with a Kd of 13 nM. This compound effectively reduces markers of liver fibrosis, including type I collagen and α-smooth muscle actin, in murine models of acute liver injury and fibrosis. Galectin-3-IN-6 serves as a valuable tool for investigating the mechanisms and potential therapies for acute liver injury and related fibrotic conditions. -
Galectin Antagonist
SNAP 398299 is a selective antagonist of the Galectin-3 (Gal3) receptor. This compound has demonstrated potential anxiolytic and antidepressant effects by partially reversing the neuropeptide galanin-induced inhibition of dorsal raphe neuronal firing as well as the galanin-induced hyperpolarizing current. Its unique mechanism makes SNAP 398299 a valuable tool for researching the roles of galectin in neurobiology and potential therapeutic interventions for mood disorders. -
Galectin Binder
Galectin-3 antagonist 2 is a compound that specifically targets galectin-3, a β-galactoside-binding lectin. This antagonist is known to inhibit the activity of galectin-3, which has been implicated in promoting the migration of B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells and contributing to drug resistance in this malignancy. It is utilized in research applications focused on cancer biology, particularly in understanding the mechanisms of leukemogenesis and the development of therapeutic strategies for leukemia. -
Gal-3 Inhibitor
Galectin-3-IN-3 is a selective inhibitor of galectin-3, exhibiting potent activity with IC50 values of 11 nM for mouse galectin-3 and 84 nM for human galectin-3. This compound serves as a valuable tool for studying the role of galectin-3 in various biological processes, including tumor progression, inflammation, and fibrosis. Its oral bioavailability allows for convenient administration in preclinical models, facilitating research in therapeutic applications targeting galectin-3-related pathologies. -
Galectin-1 Inhibitor
GB1490 is a potent galectin-1 inhibitor, exhibiting a Kd value of 0.4 μM. Additionally, it shows inhibitory activity against galectin-3 with a Kd of 2.7 μM. This compound is primarily utilized in research to investigate the role of galectins in various biological processes, including cancer progression and immune response modulation. Its selectivity and potency make it a valuable tool in studies aimed at understanding galectin-related pathways. -
Galectin-8N Inhibitor
Galectin-8N-IN-2 is a selective inhibitor of Galectin-8N, exhibiting a Ki value of 74 µM. This compound is essential for investigating the role of Galectin-8N in biological processes, particularly in modulating cell adhesion, immune responses, and tumor progression. Its inhibitory action facilitates research into therapeutic strategies targeting galectins in cancer and autoimmune diseases. -
Anti-Inflammatory Agent
Methylprednisolone aceponate is a glucocorticoid with a specific mechanism of action as a selective glucocorticoid receptor ligand, primarily functioning as an anti-inflammatory agent. It exhibits weak systemic effects, making it particularly useful in the treatment of localized inflammatory conditions. This compound is valuable for research applications targeting eczema and other inflammatory skin disorders, aiding in the understanding of their pathophysiology and potential treatments. -
Anti-inflammatory Agent
Isoflupredone acetate is a corticosteroid with potent anti-inflammatory properties. It modulates inflammatory responses and is utilized in research related to ketosis, musculoskeletal disorders, hypersensitivity, and various inflammatory diseases in animals such as cows, horses, and pigs. This compound serves as a valuable tool for studying the mechanisms of inflammation and therapeutic interventions in veterinary medicine. -
Anti-inflammatory Agent
Mazipredone free base is a glucocorticoid derivative that functions primarily as an anti-inflammatory and anti-allergic agent. It exhibits significant biological activity in reducing inflammation and managing allergic responses. This compound is particularly useful in research applications focused on inflammation-related conditions and therapeutic interventions targeting the immune response. Mazipredone free base is sensitive to oxidation and is affected by both acidic and basic environments. -
Anti-inflammatory agent
Fluocortolone is an orally active anti-inflammatory agent targeting the modulation of inflammatory responses. It is known to effectively reduce plasma fibrinogen levels and demonstrates significant efficacy in alleviating Mycobacterium butyricum-induced foot edema in rat models of adjuvanted joint inflammation, with effective dosing in the range of 3-12 mg/kg. This compound is valuable for studies related to inflammation and joint diseases. -
Anti-inflammatory Agent
Rimexolone is a glucocorticoid steroid that functions primarily as an anti-inflammatory agent. It exhibits potent anti-inflammatory properties and is employed in the management of ocular inflammation. Its formulation as a 1% ophthalmic suspension makes it suitable for targeted treatment in various inflammatory conditions affecting the eye. -
Anti-Inflammatory agent
Fluocortin butyl ester is a topical corticosteroid with anti-inflammatory properties, demonstrating minimal systemic corticosteroid activity upon application. It has shown efficacy and good tolerance in managing symptoms of perennial rhinitis, making it a valuable reagent for research focused on inflammatory responses and related conditions. -
Anti-inflammatory Agent
Prednisolone metazoate sodium is an anti-inflammatory agent primarily used in the study of inflammatory bowel disease, ulcerative colitis, and gastrointestinal disorders. This compound exerts its biological activity by modulating the immune response and reducing inflammation, making it a valuable tool in research focused on inflammatory conditions of the gastrointestinal tract. -
RIG-I Inhibitor
RIG012 is a potent inhibitor of RIG-I with an IC50 of 0.71 μM, as determined by the NADH-coupled ATPase assay. It effectively suppresses the expression of interferon beta (IFN-β) and the interferon-stimulated gene hRsad2. RIG012 is valuable for research applications focusing on the modulation of innate immune responses and the study of viral infections. -
IRF5 Inhibitor
YE6144 is a selective interferon regulatory factor 5 (IRF5) inhibitor. It exhibits significant biological activity by suppressing disease progression and is particularly effective for maintaining remission in murine models of systemic lupus erythematosus (SLE). This compound serves as a valuable tool for researchers investigating the mechanisms of SLE and the role of IRF5 in autoimmune diseases. -
IFN-γ Antagonist
IFN-γ Antagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) functions as an antagonist of interferon-γ (IFN-γ). This compound effectively inhibits IFN-γ-induced HLR/DR antigen expression in cellular models. Its application is particularly relevant in the investigation of diseases characterized by dysregulation of immune responses. -
Antiviral Agent
2'-Deoxy-2'-fluorouridine is a nucleoside analog targeting viral replication. It effectively inhibits the replication of wild-type viruses by binding to viral RNA, while also demonstrating capacity to incorporate into DNA and RNA in vivo models. Furthermore, this compound can be utilized as a precursor in the development of respiratory syncytial virus (RSV) polymerase inhibitors. Its unique mechanism makes 2'-Deoxy-2'-fluorouridine a valuable compound for antiviral research applications. -
STING Agonist
diABZI-V/C-DBCO is a potent STING agonist with an EC50 of 1.47 nM. It activates the STING pathway to promote the production of type I interferons, particularly IFN-β, enhancing immune responses. This compound acts as a substrate for cathepsin B, leading to the release of active diABZI-amine through cathepsin B-mediated cleavage. In preclinical studies using an orthotopic mouse model of breast cancer, diABZI-V/C-DBCO has been shown to elevate serum levels of IFN-β and increase the frequency of granzyme B+ CD8+ T cells, making it valuable for research in triple-negative breast cancer. -
STING Agonist
SNX281 is a selective STING agonist that functions by inducing homodimerization at the STING binding site, leading to a conformational shift that activates STING and initiates downstream signaling pathways. This compound effectively stimulates the production of type I interferons, including IFN-β, as well as TNF-α and IL-6, resulting in enhanced T cell responses and prolonged immune memory. SNX281 demonstrates anti-tumor activity and is valuable for research applications in colorectal cancer, melanoma, advanced solid tumors, lymphoma, and ovarian cancer. -
Mi-2β-targeted Inhibitor
Z36-MP5 is a targeted inhibitor of Mi-2β, exhibiting an IC50 value of 0.082 μM. This compound effectively reduces Mi-2β ATPase activity, leading to the reactivation of interferon-stimulated gene (ISG) transcription. Additionally, Z36-MP5 is known to enhance T-cell-mediated cytotoxicity, making it a valuable tool for research in immunology and potential therapeutic applications in cancer and viral infections.
